Myofibroblast transdifferentiation of mesothelial cells is mediated by RAGE and contributes to peritoneal fibrosis in uraemia

Nephrology Dialysis Transplantation

Volumn 21, Issue 9, 2006, Pages 2549-2555

  De Vriese, An S ^a,b   Tilton, Ronald G ^c   Mortier, Siska ^a   Lameire, Norbert H ^a  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

^b Renal Unit   (Belgium)

^c University of Texas Medical Branch School of Medicine   (United States)

Author keywords

AGE; Myofibroblast; Peritoneal membrane; RAGE; TGF ; Uraemia

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ADVANCED GLYCATION END PRODUCT RECEPTOR; ALPHA SMOOTH MUSCLE ACTIN; CYTOKERATIN; HYDROXYPROLINE; MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY; PLACEBO; TRANSFORMING GROWTH FACTOR BETA; ADVANCED GLYCOSYLATION END PRODUCT RECEPTOR; ADVANCED GLYCOSYLATION END-PRODUCT RECEPTOR; IMMUNOGLOBULIN RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERIOSCLEROSIS; ARTICLE; CELL DIFFERENTIATION; CELL TRANSFORMATION; CHRONIC DISEASE; CONTROLLED STUDY; FEMALE; FIBROSING ALVEOLITIS; GENE LOCATION; IMMUNOHISTOCHEMISTRY; MESOTHELIUM CELL; MYOFIBROBLAST; NEPHRECTOMY; NONHUMAN; PERITONEAL DISEASE; PERITONEAL FIBROSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; QUANTITATIVE ANALYSIS; RAT; TISSUE DISTRIBUTION; UPREGULATION; UREMIA; WESTERN BLOTTING; ANIMAL; BIOSYNTHESIS; COMPARATIVE STUDY; DISEASE MODEL; EPITHELIUM CELL; FIBROBLAST; FIBROSIS; IMMUNOBLOTTING; METABOLISM; MUSCLE FIBRIL; PATHOLOGY; PERITONEUM; WISTAR RAT;

ANIMALS; CELL DIFFERENTIATION; DISEASE MODELS, ANIMAL; EPITHELIAL CELLS; FEMALE; FIBROBLASTS; FIBROSIS; GLYCOSYLATION END PRODUCTS, ADVANCED; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; MYOFIBRILS; PERITONEUM; RATS; RATS, WISTAR; RECEPTORS, IMMUNOLOGIC; TRANSFORMING GROWTH FACTOR BETA; UREMIA;

EID: 33750134948     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfl271     Document Type: Article

References (20)

1. Williams JD, Craig KJ, Topley N et al. Morphologic changes in the peritoneal membrane of patients with renal disease. J Am Soc Nephrol 2002; 13: 470-479
2. Williams JD, Craig KJ, Von Ruhland C et al. The natural course of peritoneal membrane biology during peritoneal dialysis. Kidney Int 2003; 88 [Suppl]: S43-S49
3. Miyata T, Devuyst O, Kurokawa K, van Ypersele dS. Toward better dialysis compatibility: Advances in the biochemistry and pathophysiology of the peritoneal membranes. Kidney Int 2002; 61: 375-386
4. Nakayama M, Kawaguchi Y, Yamada K et al. Immunohistochemical detection of advanced glycosylation end-products in the peritoneum and its possible pathophysiological role in CAPD. Kidney Int 1997; 51: 182-186
5. Honda K, Nitta K, Horita S et al. Accumulation of advanced glycation end products in the peritoneal vasculature of continuous ambulatory peritoneal dialysis patients with low ultra-filtration. Nephrol Dial Transplant 1999; 14: 1541-1549
6. Park MS, Lee HA, Chu WS et al. Peritoneal accumulation of AGE and peritoneal membrane permeability. Perit Dial Int 2000; 20: 452-460
7. Ohgami N, Nagai R, Ikemoto M et al. CD36, serves as a receptor for advanced glycation endproducts (AGE). J Diabetes Complicat 2002; 16: 56-59
8. Yan SF, Ramasamy R, Naka Y, Schmidt AM. Glycation, inflammation, and RAGE: A scaffold for the macrovascular complications of diabetes and beyond. Circ Res 2003; 93: 1159-1169
9. De Vriese AS, Flyvbjerg A, Mortier S et al. Inhibition of the interaction of AGE-RAGE prevents hyperglycemia-induced fibrosis of the peritoneal membrane. J Am Soc Nephrol 2003; 14: 2109-2118
10. Flyvbjerg A, Denner L, Schrijvers BF et al. Long-term renal effects of a neutralizing RAGE antibody in obese type 2 diabetic mice. Diabetes 2004; 53: 166-172
11. Oldfield MD, Bach LA, Forbes JM et al. Advanced glycation end products cause epithelial-myofibroblast transdifferentiation via the receptor for advanced glycation end products (RAGE). J Clin Invest 2001; 108: 1853-1863
12. Yang AH, Chen JY, Lin JK. Myofibroblastic conversion of mesothelial cells. Kidney Int 2003; 63: 1530-1539
13. Margetts PJ, Bonniaud P, Liu L et al. Transient overexpression of TGF-β1 induces epithelial mesenchymal transition in the rodent peritoneum. J Am Soc Nephrol 2005; 16: 425-436
14. Yanez-Mo M, Lara-Pezzi E, Selgas R et al. Peritoneal dialysis and epithelial-to-mesenchymal transition of mesothelial cells. N Engl J Med 2003; 348: 403-413
15. Jimenez-Heffernan JA, Aguilera A, Aroeira LS et al. Immunohistochemical characterization of fibroblast sub-populations in normal peritoneal tissue and in peritoneal dialysis-induced fibrosis. Virchows Arch 2004; 444: 247-256
16. Taes YE, Delanghe JR, De Vriese AS et al. Creatine supplementation decreases homocysteine in an animal model of uremia. Kidney Int 2003; 64: 1331-1337
17. Tilton RG, Kawamura T, Chang KC et al. Vascular dysfunction induced by elevated glucose levels in rats is mediated by vascular endothelial growth factor. J Clin Invest 1997; 99: 2192-2202
18. Throckmorton DC, Brogden AP, Min B et al. PDGF and TGF-beta mediate collagen production by mesangial cells exposed to advanced glycosylation end products. Kidney Int 1995; 48: 111-117
19. Ziyadeh FN, Han DC, Cohen JA et al. Glycated albumin stimulates fibronectin gene expression in glomerular mesangial cells: Involvement of the transforming growth factor-beta system. Kidney Int 1998; 53: 631-638
20. Powell DW, Mifflin RC, Valentich JD et al. Myofibroblasts. II. Intestinal subepithelial myofibroblasts. Am J Physiol 1999; 277: C183-C201